RT Journal Article
SR Electronic
T1 Simple and Versatile Pharmacokinetic Model for Radioligand Therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.13.24308814
DO 10.1101/2024.06.13.24308814
A1 Zounek, Adrian Jun
A1 Zounek, Alexis Nikolai
YR 2024
UL http://medrxiv.org/content/early/2024/06/17/2024.06.13.24308814.abstract
AB In recent years radioligand therapy has emerged as an effective treatment modality for various solid malignancies, with pharmacokinetic modeling being routinely used for absorbed dose calculation and patient-specific therapy planning. Exemplary time-activity curves of FAP-targeted radioligands in a mouse model are accurately fitted by a sum of right skew biexponential distributions with four adjustable parameters in total. This type of modeling function is versatile and also suitable for conventional drugs. For further insight, an auxiliary equation is derived that relates tumor clearance to FAP expression and the radioligand dissociation constant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors